Equities Analysts Set Expectations for PBYI FY2025 Earnings

Puma Biotechnology, Inc. (NASDAQ:PBYI) – Investment analysts at Zacks Research raised their FY2025 earnings per share (EPS) estimates for shares of Puma Biotechnology in a research report issued to clients and investors on Thursday, January 9th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical company will post earnings per share of $0.28 for the year, up from their previous estimate of $0.26. The consensus estimate for Puma Biotechnology’s current full-year earnings is $0.31 per share. Zacks Research also issued estimates for Puma Biotechnology’s Q2 2026 earnings at $0.06 EPS.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Puma Biotechnology in a report on Monday, December 23rd. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th.

Puma Biotechnology Trading Down 5.1 %

Shares of NASDAQ PBYI opened at $3.55 on Friday. The stock has a market capitalization of $174.26 million, a P/E ratio of 7.40 and a beta of 1.10. The stock’s 50 day moving average price is $3.03 and its two-hundred day moving average price is $2.99. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. Puma Biotechnology has a 52-week low of $2.22 and a 52-week high of $7.73.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The firm had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. During the same period in the prior year, the firm posted $0.12 EPS.

Insider Transactions at Puma Biotechnology

In other news, CEO Alan H. Auerbach sold 33,841 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total transaction of $106,599.15. Following the completion of the transaction, the chief executive officer now owns 7,029,674 shares in the company, valued at approximately $22,143,473.10. This trade represents a 0.48 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $29,726.55. Following the completion of the transaction, the insider now directly owns 108,951 shares in the company, valued at $343,195.65. This represents a 7.97 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 23.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. American Century Companies Inc. increased its position in Puma Biotechnology by 98.5% in the 2nd quarter. American Century Companies Inc. now owns 738,902 shares of the biopharmaceutical company’s stock worth $2,409,000 after purchasing an additional 366,653 shares during the last quarter. Affinity Asset Advisors LLC acquired a new position in Puma Biotechnology in the second quarter worth approximately $815,000. Frazier Life Sciences Management L.P. raised its position in Puma Biotechnology by 8.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 3,062,558 shares of the biopharmaceutical company’s stock valued at $9,984,000 after acquiring an additional 246,264 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Puma Biotechnology in the third quarter valued at approximately $627,000. Finally, Great Point Partners LLC grew its position in Puma Biotechnology by 10.6% in the second quarter. Great Point Partners LLC now owns 1,486,544 shares of the biopharmaceutical company’s stock worth $4,846,000 after acquiring an additional 142,916 shares in the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.